Article

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma

2019-12-19

Abstract excerpt

Many cancer drugs only benefit a subset of the patients that receive them, but are often associated with serious side effects. Predictive classification methods that can identify which patients will benefit from a specific treatment are therefore of great clinical utility. We here introduce a novel machine learning method to identify predictive gene expression signatures, based on the idea that patients who receiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f9c2f673-1fa5-5643-849a-5ee55cbeeeb4
DOI: 10.1101/2019.12.16.19015024

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple MyelomaDOI 10.1101/2019.12.16.19015024Read

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read

Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple MyelomaSemantic proximity Read

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity Read

A gene expression signature based on cell-death related gene expression in multiple myelomaSemantic proximity Read

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signatureSemantic proximity Read

Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verificationSemantic proximity Read

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibSemantic proximity Read

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation InhibitorsSemantic proximity Read

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging SystemSemantic proximity Read

Chemogenomics Mapping of Potential Drugs and Targets for Treatment of Multiple MyelomaSemantic proximity Read

Identification of a novel cuproptosis‐related gene signature for multiple myeloma diagnosisSemantic proximity Read

Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple MyelomaSemantic proximity Read